智通财经APP获悉，近日，CDE 官网显示，罗氏(RHHBY.US)RO7795068 注射液获批临床，用于控制饮食和增加运动的基础上对肥胖或超重成人患者的长期体重管理。
资料显示，RO7795068 是 Carmot 开发的一款 GLP-1R/GIPR 双重激动剂。2023 年 12 月，罗氏 31 亿美元收购 Carmot 囊获了该产品。据悉，RO7795068 的肥胖适应症在境外已经推进到了 III 期临床阶段。II 期结果显示，每周一次皮下注射 RO7795068（剂量逐渐增加至 24mg）可使患者体重显著减轻 22.5%（疗效估计值），且在48周时未达到体重减轻平台期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.